Connor D. Flynn

Connor D. Flynn

Auto-generated profile, based on publicly available information

Connor D. Flynn

Department of Chemistry, Weinberg College of Arts and Sciences, Northwestern University, Evanston, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2023 in Nature Reviews Bioengineering
Verified
Journal Article
Open access
PDF file
CFConnor D. Flynn
Connor D. Flynn
DCDingran Chang
Dingran Chang
AMAlam Mahmud
Alam Mahmud
HYHanie Yousefi
Hanie Yousefi
Jagotamoy DasJagotamoy Das
Jagotamoy Das
SKShana O. Kelley
Shana O. Kelley
Body-based biomolecular sensing systems, including wearable, implantable and consumable sensors allow comprehensive health-related monitoring. Glucose sensors have long dominated wearable bioanalysis applications owing to their robust continuous detection of glucose, which has not yet been achieved for other biomarkers. However, access to diverse biological fluids and the development of reagentless sensing approaches may enable the design of body-based sensing systems for various analytes. Importantly, enhancing the selectivity and sensitivity of biomolecular sensors is essential for biomarker detection in complex physiological conditions. In this Review, we discuss approaches for the signal amplification of biomolecular sensors, including techniques to overcome Debye and mass transport limitations, and selectivity improvement, such as the integration of artificial affinity recognition elements. We highlight reagentless sensing approaches that can enable sequential real-time measurements, for example, the implementation of thin-film transistors in wearable devices. In addition to sensor construction, careful consideration of physical, psychological and security concerns related to body-based sensor integration is required to ensure that the transition from the laboratory to the human body is as seamless as possible.

5 June 2023 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
DCDingran Chang
Dingran Chang
Zongjie WangZongjie Wang
Zongjie Wang
CFConnor D. Flynn
Connor D. Flynn
AMAlam Mahmud
Alam Mahmud
MLMahmoud Labib
Mahmoud Labib
SKShana O. Kelley
Shana O. Kelley

15 October 2025 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
JTJiaobing Tu
Jiaobing Tu
CFConnor D. Flynn
Connor D. Flynn
JYJeonghee Yeom
Jeonghee Yeom
ZWZhenwei Wu
Zhenwei Wu
SKShana O. Kelley
Shana O. Kelley
Wei GaoWei Gao
Wei Gao

11 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
Kangfu ChenKangfu Chen
Kangfu Chen
BDBill T. V. Duong
Bill T. V. Duong
SASharif U. Ahmed
Sharif U. Ahmed
PDPiriththiv Dhavarasa
Piriththiv Dhavarasa
Zongjie WangZongjie Wang
Zongjie Wang
SKShana O. Kelley
Shana O. Kelley
Exosomal PD-L1 (exoPD-L1) has recently received significant attention as a biomarker predicting immunotherapeutic responses involving the PD1/PD-L1 pathway. However, current technologies for exosomal analysis rely primarily on bulk measurements that do not consider the heterogeneity found within exosomal subpopulations. Here, we present a nanoscale cytometry platform NanoEPIC, enabling phenotypic sorting and exoPD-L1 profiling from blood plasma. We highlight the efficacy of NanoEPIC in monitoring anti-PD-1 immunotherapy through the interrogation of exoPD-L1. NanoEPIC generates signature exoPD-L1 patterns in responders and non-responders. In mice treated with PD1-targeted immunotherapy, exoPD-L1 is correlated with tumor growth, PD-L1 burden in tumors, and the immune suppression of CD8+ tumor-infiltrating lymphocytes. Small extracellular vesicles (sEVs) with different PD-L1 expression levels display distinctive inhibitory effects on CD8 + T cells. NanoEPIC offers robust, high-throughput profiling of exosomal markers, enabling sEV subpopulation analysis. This platform holds the potential for enhanced cancer screening, personalized treatment, and therapeutic response monitoring.

7 August 2025 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
AGAmin GhavamiNejad
Amin GhavamiNejad
CFConnor D. Flynn
Connor D. Flynn
AGArmin Geraili
Armin Geraili
SMSako Mirzaie
Sako Mirzaie
FEFatemeh Esmaeili
Fatemeh Esmaeili
SKShana O. Kelley
Shana O. Kelley

16 October 2026 in ChemRxiv
Verified
Preprint
Open access
CFConnor D. Flynn
Connor D. Flynn
SKShana O. Kelley
Shana O. Kelley
DCDingran Chang
Dingran Chang
Nucleic acid aptamers provide a simple, cost-effective alternative to antibodies for targeting biomolecular analytes from ions to large protein complexes. However, the interactions of these nucleic-acid based structures in vivo remains largely uncharacterized. Here, we report the seemingly pervasive electrostatic association between nucleic acids and high isoelectric point proteins under biological conditions. Such non-specific binding runs the risk of convoluting aptamer selection and validation, while also potentially interfering with nucleic acid-based nanotechnologies in vivo. Through our explorations, we identify several methods to disentangle sequence-specific aptamer interactions from non-specific electrostatic association, allowing for discrimination between binding modes. We also identify dissociation rate (koff) and equilibrium binding response (Req) as potentially better discriminators than KD for isolating and validating true sequence-specific aptamers.